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Summary 
 This paper analyses data on 2,226 cases of Hepatitis B virus (HBV) infection detected 
during the years 1970 to 1987. Of those where information on risk-group was available (1,301), 
infection among intravenous drug-abusers accounted for the largest proportion (49%). Most 
became infected during and since an outbreak of hepatitis B and Delta hepatitis which originated 
in this group in 1980. A comparison of the data before and after the start of the outbreak among 
drug-abusers shows a marked increase in the number of HBV infections in non drug users, 
including haemophiliacs, homosexuals and health-care staff, and a dramatic decrease in hepatitis 
B following blood transfusion. A larger group (165 cases), many of whom are long-term healthy 
hepatitis B surface antigen carriers, were patients in institutions for the mentally handicapped 
(IMH). Most were detected recently during pre-vaccination sampling programmes. Others 
affected included visitors to and from high-incidence areas, tattooed persons, dialysis patients, 
persons born to infected mothers, and members of the security forces dealing with drug-abusers. 
 In all, 8.4% of the hepatitis B cases detected were found to be carriers and 67% of these 
remained carriers in 1987. The mean duration of carriage was 3.25 years. Intravenous drug-
abusers and IMH patients constituted the two largest groups of carriers. 
 The running-three-yearly mean incidence of new cases of hepatitis B has levelled off 
below the peak of 1981. Although the number of cases among drug-abusers has apparently 
decreased, the number of cases among non drug-abusing groups has increased by 50%. The use 
of recently introduced vaccines in some risk groups should help to reverse this upward trend. 
Introduction 
 Routine tests for hepatitis B became available in Ireland in 1970. Five of the first16 
hepatitis B surface antigen (HBsAg) positive cases and two of Five anti-HBs positive cases 
detected up to August 1972 occurred in persons who had received blood; only three HBsAg 
positives were drug-abusers1. Among intravenous drug-abusers a very large increase in hepatitis 
B cases occurred in 1980 due to the increased availability and use of heroin by injection2. At the 
same time the Hepatitis D virus (HDV, Delta agent) was introduced and caused coinfection in up 
to 36% of cases2,3. By 1983, there was evidence that the increase in incidence of hepatitis B 
among drug-abusers was also causing an increase in cases among their contacts4. 
 This paper details the epidemiology of all hepatitis B cases detected at the Virus Reference 
Laboratory since 1970, notes the changes in incidence of HBsAg in various risk-groups during 
this lime and identifies those risk-groups which are most affected in Ireland at present. 
Patients and Methods 
 Specimens included in this study were sent to the Virus Reference Laboratory (VRL) at 
this Department, for hepatitis serology by clinicians in hospitals and general practice, in sexually 
transmitted disease (STD) clinics and in institutions for the mentally handicapped (IMH), from 
1970 to 1987 inclusive. The blood transfusion services referred samples to us for confirmation 
from donors found initially positive or possibly positive for hepatitis B surface antigen by 
screening tests. 
 A total of 64,897 specimens have been tested for hepatitis by us since 1970. Lack of 
clinical and sociological information made it impossible to classify fully 638 of the 2,226 
hepatitis B cases detected. These are referred to as “unknown” in Tables I and V. Patients with 
markers of past hepatitis B infection are not included in this study. 
 Hepatitis B surface antigen (HBsAg) was originally assayed by a semi-
microimmunodiffusion (ID) test on concentrated sera. supplemented from 1974 with a 
haemagglutination test (Hepatest, Wellcome). These were replaced in March 1979 by 
radioimmunoassay (RIA) (Abbott, Ausria II) and from July 1985 by enzyme-immunoassay (EIA, 
Abbott, Roche and Wellcome). HBsAg positives are always confirmed by neutralising assay, or 
by repeat testing and by serology for other hepatitis B markers, i.e.: Hepatitis Be antigen 
(HBeAg), anti-HBe, and antibody to hepatitis B core (anti-HBc) IgG and IgM by in-house ElA’s5. 
An HBsAg carrier is defined as a case where HBsAg is detected in the blood at approximately the 
same level for six months or more. Healthy carriers arc characteristically negative for HBeAg and 
anti-HBc IgM 
 Statistical analyses were carried out using Students l tests. 
Results 
 Since 1970,2,226 patients have been found to be HBsAg positive, one of which was 
retrospectively detected from 1969. Of those where information on the risk group was known, 
872 (49%) were drug-abusers. It can be seen from Fig. 1 and Table I that the incidence of 
hepatitis B in drug-abusers first exceeded that in non drug-abusers in 1980 and peaked between 
1981 and 1983 (67-75% of total cases). After 1983, the incidence of hepatitis B in drug-abusers 
appeared to fall, while that in non-abusers rose. However, extensive enquiries during 1981-84 
about the then “unknown” cases showed that many were in fact drug-abusers; figures in the 
“Unknown” group from 1984 to 1987 in Table I therefore almost certainly contain a significant 
but unknown number of drug-abusers. Overall, there has been a 15-fold increase in the number of 
hepatitis B cases among drug-abusers since 1980. The number of cases among non drug-abusers 
over the same period has increased by 50% (Table II). The running-three-yearly mean incidence 
of hepatitis B has remained at a level somewhat below that of the peak in 1981(Fig. 1). 
 
 
 
 
  
 
TABLE I 
New HBsAG positives detected per year. 
Year Unknown IVDA IMH Donors PTHB HMX/STD Haem/iac Visitors HCS Misc. Total 
1969 0 0 1 nt 0 0 0 0 0 0 1 
1970 1 0 0 nt 0 0 0 0 0 1 2 
l97l 4 1 0 nt 2 0 1 0 1 0 9 
1972 7 3 2 4 2 1 1 2 0 0 22 
1973 12 2 6 13 4 0 I 0 4 11 53 
1974 30 1 1 26 2 0 2 0 2 4 68 
1975 26 6 3 20 4 0 3 3 3 1 69 
1976 36 9 1 30 3 0 0 0 5 2 86 
1977 16 11 1 17 1 0 2 0 3 2 53 
1978 18 16 2 24 3 1 0 4 4 7 79 
1979 20 14 1 12 1 1 0 0 1 2 52 
1980 25 42 1 29 0 0 0 1 3 0 101 
1981 54 217 3 24 2 5 1 5 6 6 323 
1982 36 168 1 8 0 2 3 5 1 0 224 
1983 27 165 0 11 0 2 6 2 3 4 220 
1984 90x 75 3 18 0 4 7 6 7 1 211 
1985 77x 58 8 16 0 5 1 2 4 5 176 
1986 87x 34 81 21 0 14 5 11 6 5 264 
1987 72x 50 50 8 0 16 3 9 4 1 213 
Totals 638 872 165 281 24 51 36 50 57 52 2226 
Unknown = Insufficient or no information supplied or status unconfirmed; the ‘x’ indicates the inclusion of a 
significant but unknown number of intravenous drug-abusers (IVDA), see text. IMH = patients from institutions for the 
menially handicapped. PTHB = post-transfusion hepatitis B, HMX/STD = homosexuals and attenders at sexually 
transmitted disease clinics. Haem/iac = haemophiliacs. HCS = health-care staff. Visitors = visitors to or natives from 
high-incidence areas, nt = none tested. Misc. as listed in Table IV. 
 There have been increases in incidence of hepatitis B cases among most risk groups: fifty-
one cases were seen among homosexuals and those attending sexually transmitted disease (STD) 
clinics. Forty-eight of these cases occurred after 1980, which was a 20-fold increase in incidence 
before 1980. The male to female ratio was 25 : 1 and the mean age was 33 years (range 20-50 
years). 
 Significant increases were also seen among haemophiliacs (three-fold), health-care staff 
(almost two-fold) and among visitors to and those native from high-incidence areas (five-fold). A 
total of 57 cases of hepatitis B were detected among health-care staff (Table III). Twenty-three 
cases (40%) were detected among nurses, 26% among doctors and surgeons .and 19% in 
laboratory staff. This data includes cases occurring among missionaries involved in health care 
returning from high incidence areas. 
 Among the miscellaneous group (Table IV), three clusters of cases occurred among 
persons who had been tattooed approximately three months earlier. These occurred in 1978 (three 
cases), 1981 (four cases) and 1983 (three cases). A total of 15 cases in the miscellaneous group 
were spouses of family contacts of acute cases of carriers. Of these, five were children born to 
infected mothers and all five became carriers (Table V). Thirteen cases were referred as part of an 
outbreak of 37 cases of hepatitis B which occurred in a tuberculosis unit and have been reported 
previously6. One of the three priests in Table IV was involved in social work with drug-abusers; 
the source of infection of the other two is unknown but many of those included in Table I, as 
visitors to foreign areas of high-incidence, were also priests. 
 Although testing for HBsAg or anti-HBs is not routinely necessary prior to vaccination, we 
have carried out tests on samples from residents in a number of institutions for the mentally 
handicapped (IMH) to confirm the expected high incidence, as seen elsewhere7. HBV infection 
was confirmed in 115 residents (12.5%). The mean age of those infected was 35 years and the 
ratio of males to females was 1.5 : 1. The  
TABLE II 
Incidence of Hepatitis B before and after the outbreak among Drug-abusers. 
 Pre-outbreak Post-outbreak 
HBsAg positives in: 1970-79 1980-87* p** 
Drug abusers 63 809 <0.001 
Homosexuals and STD clinic attenders 3 48 <0.001 
Visitors to and natives from high-incidence areas 9 41 <0.05 
Haemophiliacs  1020 <0.05 
Health-care staff 23 34 <0.05 
Miscellaneous 30 22 not done 
Blood donors 146 135 N.S. 
Post-transfusion 22 2 <0.01 
Total of non-drug-abusers 243 302  
* Note that this period is two years shorter than the pre-1980 period. 
** by Student’s l lest. N.S. = No significant difference 
 
TABLE III 
Hepatitis B among Health-Care Staff before and since 1980. 
 Pre-outbreak Post-outbreak  
 1970-79 1980-87 Total 
Nurses 7 9 16 (28%) 
Nurses (IMH)* 3 4 7 (12%) 
Lab. Staff 4 7 11 (19%) 
Doctors 5 7 12 (21%) 
Surgeons 0 3 3 (5%) 
Others and Unspecified 4 4 4 8 (14%) 
Totals 23 23 34 57 
* Nurses working in institutions for the mentally handicapped. 
serological pattern indicated that most were long-term healthy carriers of HBsAg although some 
had HBeAg and IgM anti-HBc, indicating infectivity. As discussed below, IMH patients are 
excluded from Figure 1 because many of those detected in 1986 and 1987 were long-term 
carriers. 
 The HbsAg positivity rate among donors in Ireland has been found to be only one per 
10,000 (0.01%), which-is one of the lowest rates in the world (Dr. T. Walsh, Blood Transfusion 
Service, Dublin, personal communication). Specimens from a total of 281 donors were referred to 
us by the Blood Transfusion Service for confirmation tests and there has been a small decline in 
the number of positives detected annually but the decrease is not statistically significant. However 
the number of post- 
TABLE IV 
Miscellaneous Hepatitis B cases. 
Category No. 
Tuberculosis unit patients 13 (25%) 
Recently tatooed* 10 (19%) 
Dialysis patients 8 (15%) 
Spouses of HBsAg positives 7  
Other family contacts, Including babies 8 (29%) 
Priests 3 (5.7%) 
Police 1 (2%) 
Prison Staff 1 (2%) 
Diabetic 1 (2%) 
Total 52  
* Associated with three clusters, see text. 
transfusion hepatitis B cases has decreased significantly since 1980, with no cases detected since 
1981. 
 Among all HBsAg positives detected, 170 (8.3%) were found to be HBsAg carriers and, of 
those tested in 1987, 67% remained carriers. The largest groups of carriers were drug-abusers 
(29%) and IMH patients (26%). Only five donors are listed as carriers, a figure which is likely to 
be an underestimate for reasons discussed below. The minimum mean duration of carriage was 
3.25 years, with one being followed up for 17 years. All cases of vertical transmission detected in 
this study have become carriers. 
 
Discussion 
 Our data show that the mean annual incidence of hepatitis B has quadrupled since 1980, 
compared with the ten years before 1980. Although some of this increase may be due to greater 
awareness resulting in more testing, most is a result of the 15-fold increase in hepatitis B 
infections in an expanded population of intravenous drug-abusers. Prior to 1980 only 20% of 
HBsAg positives were intravenous drug-abusers, whereas since 1980, 72% of HBsAG positives 
were associated with intravenous drug-abuse and, additionally, 36% were also infected with 
hepatitis D3. Although there has been a reduction in the number of hepatitis B cases detected 
among drug-abusers since 1983, it may not reflect the true incidence, because of the probability 
that many cases in the “unknown” risk group may also be drug-associated. 
 We have also seen increases in hepatitis B cases in many non drug-abusing groups: the 
largest increase in incidence of hepatitis B has been among homosexuals and attenders at STD 
clinics, although the total number of positives (51) is not large compared with the number of 
cases among drug-abusers. However, the early figures may not be truly representative because the 
national STD service was not as well developed prior to 1980, or as freely used as in recent limes, 
and there has since been a greater awareness of the possibilities of spread of hepatitis B by sexual 
contact. 
 Hepatitis has been recognised as a problem in institutions for the mentally handicapped 
since the identification of two types of hepatitis in patients at the Willowbrook State School by 
Krugman in the 1960’s8. Occasional cases of acute hepatitis B have been detected in residents of 
such institutions in the  
TABLE V 
HBsAG Carriers in each Group. 
Group No. Male/Fem.
Mean 1987 
Age (range) 
Mean duration of 
Carriage (range) mts. 
No. known still 
positive in 
1987 (%) 
Drug-abuser 50 46/4 29.2 (21-39) 35 (6-108) 17 (34%) 
IMH 44 32/12 38.3 (13-80) 20(6-180) 36 (89%) 
Donors 5 4/1 insf. ages 55 (9-108) 1 (20%) 
PTHB 2 1/1 53.0 (46, 60) 52 (7-96) 0 
Hmx/STD 7 7/0 38.3 (24-61) 21 (6-72) 4 (57%) 
Haemophiliac 8 8/0 28.0 (7-48) 31 (17-38) 5 (62%) 
Visitors 3 3/0 41.6(30-61) 63 (10-132) 0 
HCS 6 4/2 44.6 (30-66) 26 (9-48) 4 (67%) 
Peri./vert. 5 3/2 8.4(2-18) 62 (10-204) 5(100%) 
Misc. 7 4/3 30.3 (7-43) 33 (6-108) 3 (43%) 
Unknown 33 23/10 46.7 (7-80) 32(6-120) 14 (42%) 
Total 170 135/35 35.8 (2-80) yrs. 39 (6-204) months 88 (67%) 
Peri./vert = perinatal or other vertical transmission. Other abbreviations as in Table I. 
Republic and follow-up of immediate contacts of these cases at the time revealed other sub-
clinical cases or carriers (Table I). Because of the recent introduction of hepatitis B vaccines a 
number of institutions were screened for hepatitis B markers in 1986 and 1987, preparatory to the 
use of vaccine. This revealed many more positives, with follow-up serology indicating that the 
majority were carriers. Some of these also had HBeAg and IgM anti-HBc, indicating infectivity 
and they constitute a considerable reservoir of infection in such institutions. Screening has 
revealed positive cases, mostly carriers, in all but one of 15 institutions sampled but there is no 
evidence to suggest that there has been any change in incidence in these institutions. The numbers 
of positives in institutions for me mentally handicapped in Table I, for 1986 and 1987, are 
relatively high because of the recent screenings and arc therefore excluded from Figure 1 so as 
not to raise the real trend in population incidence. We have also found an increased incidence of 
hepatitis B infection among visitors to high-incidence arras of hepatitis B and among natives of 
such areas residing in Ireland. This increase may have been caused partly by increased foreign 
travel. Furthermore, many of these cases were missionaries visiting high-incidence areas, such as 
Africa, and some of them have also been involved in health-care in these areas. It is therefore 
difficult to be certain if their hepatitis B was acquired solely by health-care exposure. In such 
high-incidence areas, the risk of exposure to HBV in any one perenteral accident is increased, 
compared with such accidents in low-incidence areas. 
 Despite a much better awareness of the dangers of parenteral exposure and the adoption of 
general safety precautions by health-care staff when handling blood, the incidence among health-
care staff has increased by 43% since 1980. However the potential exposure rate has increased 
about four-fold in this time due to the quadrupling of numbers of cases. Although a 43% increase 
in incidence compared with a four-fold increase in potential exposure is actually a decreased 
infection rate, it is far from satisfactory and serves to emphasize the real need for hepatitis B 
vaccination in health-care staff. A high incidence of hepatitis cases in Irish laboratories during the 
period 1975 to 1985 was also noted in the results of a recent questionnaire which included non-A, 
non-B hepatitis cases but no hepatitis B serology9. 
 There has also been a three-fold increase in the numbers of hepatitis B cases among 
haemophiliacs. Prior to 1980 nearly all blood products administered to haemophiliacs in the Irish 
Republic were prepared from native blood (I. Temperley, personal communication). Imported 
factor VIII concentrates are thought to have been responsible for some of the increase in numbers 
of hepatitis B cases, including at least two cases caused by a batch of imported concentrate which 
was subsequently found to be HBsAg positive. 
 Parenteral spread of hepatitis B, other than by IV drug-abuse or blood product usage, was 
well illustrated by the three clusters of cases occurring among persons with recent tattoos, 
indicating lack of sterilisation of tattooing needles as being the likely cause of these cases. It is 
worth emphasising that hepatitis B was only seen in tattooed persons where the tattooing was 
recent and not in cases where old tattoos were present. The presence of an old tattoo per se does 
not therefore constitute a requirement for testing. 
 Although eight cases have been associated with renal dialysis patients, some of whom have 
been visitors to Ireland, dialysis units in the Republic are being maintained with rigorous 
precautions, including a regular HBsAg screening programme, and are fortunately ‘clean’ by 
comparison with units in many countries. 
 Heterosexual transmission is believed to have occurred in 10 of 15 family contact cases, 
where one spouse either had clinical hepatitis within the previous six months or was known to be 
a carrier. The remaining five were all born to HBsAg positive mothers. Vertical transmission is 
frequently associated with subsequent carriage, and this was confirmed in all five cases. 
 We have not detected any HBsAg positive cases among dentists, although they have been 
shown elsewhere to be at increased risk of acquiring hepatitis B10. Prior to 1973, clinical hepatitis 
B was more frequently seen in the general population after the transfusion of infected blood and 
less often in intravenous drug-abusers’. Notwithstanding this, Ireland has one of the lowest rates 
of HBsAg positivity among blood donors in the world (0.01%). As expected, mass-screening of 
donated blood for HBsAg by the blood transfusion centres since 1973 has resulted in a dramatic 
reduction in post-transfusion hepatitis B. Indeed, no such cases have been detected since 1981. 
Although the number of positives referred to us by the blood transfusion services has decreased a 
little since 1980, the change is not statistically significant. This may seem a somewhat surprising 
finding, since spread from the drug-abusing group to the general population is an often mooted 
explanation for the increase in hepatitis B seen in non drug-abusing groups. Therefore one would 
expect to see an increase in the numbers of positive donors, but this did not occur. Direct 
evidence to clarify this could be gained by determining if there has been an increase in the 
proportion of non drug-abusers with the “ay” HBsAg subtype, which was predominant in drug-
abusers, while non drug-abusers were mainly of the “ad” subtype11, but this has not been carried 
out. It is not known what proportion of positive donors are followed up by their GP’s and hence 
their source of infection is unknown to us. Since repeated testing is required to determine carrier 
status, if any, it is also unknown what proportion of HBsAg positive donors are carriers. Hence 
only five donors appear as “carriers” in Table V. However, tests have shown an absence of IgM 
anti-HBc and the presence of anti-HBe in many HBsAg positive donors (data not shown), 
suggesting that many of the HBsAg positive donors listed in Tables I and II are in fact healthy 
carriers. 
 Our data clearly shows that, in the Irish Republic, as elsewhere, hepatitis B is almost 
entirely acquired as a result of parenteral exposure (IV drug-abuse, accidentally or in institutions 
for the menially handicapped) or by sexual contact or vertically and that the risk of acquiring 
hepatitis B post-transfusion in now minimal. Haemophiliacs have been at risk from imported 
concentrates; health-care staff, especially nurses and doctors have become infected from all risk-
groups and members of the prison service and police force have also become infected by 
parenteral contact with drug-abusers. Hepatitis B vaccines now provide the means of eliminating 
the risk of acquiring hepatitis B occupationally or by social habits and are therefore being used in 
many at-risk groups in Ireland. In the future, therefore, we expect to see reductions in the 
incidence of hepatitis B in those groups in whom the vaccines are used. 
Acknowledgements 
 We are grateful to Mr. John Keating and Dr. T. Walsh, Blood Transfusion Service Board, 
Pelican House, Dublin, for assistance with the donor data; lo Professor I. Temperley, National 
Haemophilia Treatment Centres, for information on haemophiliacs and to Dr. M. Kelly and Dr. J. 
O’Connor of the Drug Advisory and Treatment Centre, Dublin. We are also grateful to the many 
clinicians and GP’s from all over Ireland who have assisted us with information on individual 
cases over the years and to those technicians involved in the laboratory work over this period, 
including Carol Mongan, Sonia Murray, Noel Campbell, Peter Quinn, Ann Conroy and Deirdre 
Roy. Thanks also to Seamus Dooley for discussion and to Pat Costigan for the figure. 
 
References 
1. Shattock, A, G, Hepatitis associated antigen in the Republic of Ireland: a preliminary report. Irish J. Med. Sci. 
1974: 143,162-167. 
2. Shattock, A. G., Kelly, M. G., Fielding, J., Arthurs, Y. Epidemic Hepatitis B with Delta-antigenaemia among 
Dublin drug-abusers. Irish J. Med. Sci. 1982: 151, 334-338. 
3. Shattock. A. G., Irwin, F. M., Morgan, B. M., Hillary, I. B., Kelly, M. G., Fielding. J. P., Kelly, D. A., Weir, D. 
G. Increased severity and morbidity of acute hepatitis in drug-abusers with simultaneously acquired hepatitis B 
and hepatitis D virus infections. Brit. Med. J. 1985: 290, 1377-1380. 
4. Kelly. D. A., Carroll, D., Shattock, A. G., O’Connor, E., Weir, D. G. A secondary outbreak of hepatitis B 
among contacts of drug-abusers in Dublin. Irish Med. J. 1983: 76, 205-208. 
 
5. Smith, A, M., Tedder, R. S. Development of an enzyme-immunoassay (ELISA) for hepatitis Be antigen and 
antibody. J. Virol. Methods. 1981: 3, 1-11. 
6. Fitzgerald, G. R., Grimes, H., Reynolds, M., Hitchcock, H., McCarthy, C. F. Hepatitis-associated antigen 
positive hepatitis in a tuberculosis unit. Gut 1975: 16, 421-428. 
7. McGregor, M. A. Hepatitis B in a hospital for the mentally subnormal in south Wales. J. Ment. Def. Res. 1988: 
32, 75-77. 
8. Krugman, S., Giles, J. P., Hammond, J. Infectious hepatitis: Evidence for two district clinical, epidemiological 
and immunological types of infection. JAMA 1967: 200, 365. 
9. Jackson, I. Occupationally acquired viral hepatitis in Irish pathology laboratories. Converse; Bulletin of the 
Academy of Medical Laboratory Science. April 1987: 4-5. 
10. Feldman, R. E., Schiff, E. R. Hepatitis in denial professionals. JAMA 1975:232, 1228-1230. 
11. Shattock. A. G., Gorry, H. F. Hepatitis B antigen (HBAg) in the Republic of Ireland: distribution of ad and ay 
subtypes. Irish J. Med. Sci. 1974: 143, 4, 214-219. 
